Related Experiment Video
Updated: Mar 24, 2026
05:10
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
10.3K
Disease-drug database for pharmacogenomic-based prescribing.
S Hussain1, B B Kenigsberg2, K Danahey1,3
1Center for Personalized Therapeutics, University of Chicago, Chicago, Illinois, USA.
Clinical Pharmacology and Therapeutics
|March 5, 2016
Summary
A new pharmacogenomic tool aids prescribing by linking diseases to drugs with genetic information. This clinical decision-support system enables personalized medicine by providing actionable treatment recommendations for over 90% of patients.
Area of Science:
- Pharmacogenomics
- Clinical Decision Support
- Precision Medicine
Background:
- Healthcare providers need better tools for interpreting pharmacogenomic data.
- Current methods for integrating genetic information into prescribing are limited.
Purpose of the Study:
- To develop and validate a novel disease-drug association tool for pharmacogenomic-based prescribing.
- To assess the tool's utility in treating common diseases with actionable genetic insights.
Main Methods:
- Mapped 324 drugs to 484 diseases, annotating associations with pharmacogenomic data.
- Applied the tool to a cohort of over 1,000 patients at a tertiary medical center.
- Integrated clinical patient genotypes with the disease-drug association tool.
Main Results:
- An average of 1.8 pharmacogenomically annotated drugs were linked per disease.
- The tool identified appropriate pharmacogenomic-guided treatments for 90% of common diseases and >=93% of patients.
- Demonstrated feasibility of delivering patient-specific, pharmacogenomically informed treatment recommendations.
Conclusions:
- The developed tool effectively supports pharmacogenomic-based prescribing for common diseases.
- This approach facilitates the integration of precision medicine into routine clinical practice.
- The tool has the potential to improve patient outcomes by enabling personalized treatment strategies.
More Related Videos
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
76
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
76
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
108
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
108
01:29Pharmacogenetics and Pharmacogenomics: Overview
137
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
137
01:27Pharmacogenetics of Drug Metabolism: Overview
106
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
106
01:27Principles of Pharmacogenetics: Types of Genetic Variants
87
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
87
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
125
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
125